Anti-Mouse PD-1 Antibody (RMP1-14)
Based on 27 publication(s) in Google Scholar
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.
For research use only. We do not sell to patients.
- Purity: 99.63%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse PD-1 Antibody (RMP1-14)
More- Cell. 2026 Jan 22;189(2):418-434.e24. [Abstract]
- Cancer Commun (Lond). 2025 Jul 24. [Abstract]
- Nat Cell Biol. 2025 Apr;27(4):668-682. [Abstract]
- J Nanobiotechnology. 2025 Jun 13;23(1):443. [Abstract]
- J Nanobiotechnology. 2025 Mar 11;23(1):201. [Abstract]
- Theranostics. 2025 Jan 2;15(4):1456-1477. [Abstract]
- Adv Sci (Weinh). 2026 Jun 18:e76025. [Abstract]
- Cell Rep Med. 2026 Mar 17;7(3):102635. [Abstract]
- Cell Rep Med. 2026 Feb 17;7(2):102621. [Abstract]
- Biomaterials. 2025 Jan:312:122740. [Abstract]
- Biomaterials. 2024 Oct:310:122625. [Abstract]
- J Control Release. 2025 Jul 10:383:113775. [Abstract]
- J Immunother Cancer. 2025 Sep 10;13(9):e011831. [Abstract]
- Proc Natl Acad Sci U S A. 2026 Jan 27;123(4):e2519625123. [Abstract]
- Oncogene. 2025 Oct;44(38):3580-3597. [Abstract]
- Int J Surg. 2025 Nov 20. [Abstract]
- Int J Surg. 2025 Jul 9. [Abstract]
- Cancer Cell Int. 2025 Jun 3;25(1):200. [Abstract]
- J Agric Food Chem. 2025 Jun 18;73(24):15125-15137. [Abstract]
- Biochem Pharmacol. 2026 Jul:249:117925. [Abstract]
- Eur J Pharmacol. 2023 Dec 5:960:176128. [Abstract]
- J Cell Mol Med. 2026 Feb;30(3):e71050. [Abstract]
- Oncol Rep. 2024 Nov;52(5):149. [Abstract]
- Clin Exp Med. 2025 Aug 13;25(1):291. [Abstract]
- Biochem Biophys Res Commun. 2026 Aug 27:828:154109. [Abstract]
- J Thorac Dis. 2026 Mar 31;18(3):243. [Abstract]
- Res Sq. 2025 Jul 17.
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
-
RT-PCR
-
IF
-
WB
Biological Activity
Rat IgG2a kappa
Mouse
PD-1
Anti-Mouse PD-1 Antibody (RMP1-14) (50-200 μg/mouse, intradermal injection, single dose) induces acute itch in mouse models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse CT26.CL25 liver metastasis model[1]
-
Dosage:10 mg/kg
-
Administration:ip, every 3 days for 3-4 doses
-
Result:Failed to significantly change immune cells when used alone.
Increased the M1/M2 ratio, increased the number of mature CD4+ T cells and CD8+ T cells, increased the expression of IFN-γ and TNF-α when used with the combination of CAPOX.
-
Animal Model:C57BL/6J mouse models[2]
-
Dosage:50-200 μg/mouse
-
Administration:intradermal injection, single dose
-
Result:Increased the number of spontaneous scratching in mice.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay, Research in vivo
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse PD-1 Antibody (RMP1-14)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (27)
-
Journal Impact Factor
-
Most Recent
-
Cell
Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. [Abstract]2026 Jan 22;189(2):418-434.e24. PMID: 41448182
Anti-Mouse PD-1 Antibody (RMP1-14) purchased from MedChemExpress. Usage Cited in: Cell. 2026 Jan 22;189(2):418-434.e24. [Abstract]
Aslfl/flFoxp3YFP-Cre or littermate Aslwt/wtFoxp3YFP-Cre mice treated with or without Anti-PD-1 antibody (200 μg, i.p.) were subcutaneously inoculated with Hep-53.4 cells (1 × 106), the tumor volume was evaluated every three days. Proportion of Tregs and ammonia levels in the subcutaneous tumors on day 18 were analyzed (n = 6).
Anti-Mouse PD-1 Antibody (RMP1-14) purchased from MedChemExpress. Usage Cited in: Cell. 2026 Jan 22;189(2):418-434.e24. [Abstract]
Hematoxylin and eosin (H&E) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining evaluated HCC tissues from patients treated with or without PD-1 (200 μg, i.p.) therapy. Elevated tissue ammonia and increased tumor-infiltrating Tregs accordingly.
-
Cancer Commun (Lond)
m6A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma. [Abstract]2025 Jul 24. PMID: 40703029 -
Nat Cell Biol
2025 Apr;27(4):668-682. PMID: 40033100 -
J Nanobiotechnology
Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems. [Abstract]2025 Jun 13;23(1):443. PMID: 40514658 -
J Nanobiotechnology
Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction. [Abstract]2025 Mar 11;23(1):201. PMID: 40069859
Anti-Mouse PD-1 Antibody (RMP1-14) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Mar 11;23(1):201. [Abstract]
IL-6 and TNF-α levels increased of PFC and serum in MIA offspring mice after PD-1 (1 μg/106 cells, 24 h) Ab alone or PD-1 Ab + MSC-EVs administration.
Anti-Mouse PD-1 Antibody (RMP1-14) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Mar 11;23(1):201. [Abstract]
Immunostaining analysis of the level of Iba-1+, the microglial soma size, branch number, and total branch length were significantly increased in PD-1 Ab (1 μg/106 cells, 24 h) group.
Anti-Mouse PD-1 Antibody (RMP1-14) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Mar 11;23(1):201. [Abstract]
Western blot analysis p-ERK/ERK level elevated in primary microglia after PD-1 (1 μg/106 cells, 24 h) Ab alone or PD-1 Ab + MSC-EVs intervention.
-
Theranostics
Ultrasound-activated erythrocyte membrane-camouflaged Pt (II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death. [Abstract]2025 Jan 2;15(4):1456-1477. PMID: 39816689 -
Adv Sci (Weinh)
Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2-Selective Small Molecule Inhibitor. [Abstract]2026 Jun 18:e76025. PMID: 42314051 -
Cell Rep Med
Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms. [Abstract]2026 Mar 17;7(3):102635. PMID: 41747719 -
Cell Rep Med
Bacterial vesicles from intratumoral L. salivarius enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer. [Abstract]2026 Feb 17;7(2):102621. PMID: 41707647 -
Biomaterials
An ultra-long-acting L-asparaginase synergizes with an immune checkpoint inhibitor in starvation-immunotherapy of metastatic solid tumors. [Abstract]2025 Jan:312:122740. PMID: 39096839 -
Biomaterials
Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway. [Abstract]2024 Oct:310:122625. PMID: 38820768 -
J Control Release
Metal-phenolic networks reverse the immunosuppressive tumor microenvironment via dual metabolism regulation and immunogenic cell death. [Abstract]2025 Jul 10:383:113775. PMID: 40294797 -
J Immunother Cancer
Enhancing immunotherapy efficacy in NSCLC through the combined use of phenelzine and Akkermansia muciniphila to regulate gut microbial metabolite 5-HIAA. [Abstract]2025 Sep 10;13(9):e011831. PMID: 40930748 -
Proc Natl Acad Sci U S A
Bioresponsive immunomodulator nanocomplex for selective immunoengineering in metastatic lymph nodes. [Abstract]2026 Jan 27;123(4):e2519625123. PMID: 41557810 -
Oncogene
2025 Oct;44(38):3580-3597. PMID: 40760092 -
Int J Surg
Unveiling macrophage-fibroblast-driven inflammatory networks mediated pan-cancer immune features by integrated single-cell and bulk RNA sequencing. [Abstract]2025 Nov 20. PMID: 41263399 -
Int J Surg
Distinct roles of HMOX1 on tumor epithelium and macrophage for regulation of immune microenvironment in ovarian cancer. [Abstract]2025 Jul 9. PMID: 40638251 -
Cancer Cell Int
Pericytes in castration-resistant prostate cancer associated with disease progression and immunotherapy response: insights from single-cell analysis. [Abstract]2025 Jun 3;25(1):200. PMID: 40462105 -
J Agric Food Chem
Combination of Ginsenoside Compound K and Anti-PD1 Inhibits Pancreatic Cancer by Activating CXCL13-CXCR5 Signaling Axis. [Abstract]2025 Jun 18;73(24):15125-15137. PMID: 40474585 -
Biochem Pharmacol
Recruitment of tumor-associated macrophages via the CCL4-CCR5 axis promotes immune escape through PD-1 signaling in lung adenocarcinoma. [Abstract]2026 Jul:249:117925. PMID: 41876018 -
Eur J Pharmacol
Mechanisms of the PD-1/PD-L1 pathway in itch: From acute itch model establishment to the role in chronic itch in mouse. [Abstract]2023 Dec 5:960:176128. PMID: 37866747 -
J Cell Mol Med
Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4/NF-κB/IL-6/STAT3 Signalling Cascade. [Abstract]2026 Feb;30(3):e71050. PMID: 41645802 -
Oncol Rep
The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence. [Abstract]2024 Nov;52(5):149. PMID: 39301655 -
Clin Exp Med
Metabolic reprogramming of arachidonic acid in clear cell renal carcinoma promotes an immunosuppressive microenvironment by activating MDK signaling pathway. [Abstract]2025 Aug 13;25(1):291. PMID: 40802073 -
Biochem Biophys Res Commun
Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line. [Abstract]2026 Aug 27:828:154109. PMID: 42259198 -
J Thorac Dis
Yifei Sanjie Formula in improving the response to PD-1 blockade by lung cancer through the attenuation of the USP7-NR1H4-bile acid metabolism axis. [Abstract]2026 Mar 31;18(3):243. PMID: 41988276 -
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Park SJ, et al., Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway. Biomaterials. 2024 Oct;310:122625. [Content Brief]
[2]. Xu ZH, et al., Mechanisms of the PD-1/PD-L1 pathway in itch: From acute itch model establishment to the role in chronic itch in mouse. Eur J Pharmacol. 2023 Dec 5;960:176128. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)